ÂÜÀòÂÒÂ×

Anthony Caggiano, MD, PhD has over 20 years of experience in the biopharmaceutical industry. Anthony is currently the Chief Medical Officer and Head of R&D at Cognition Therapeutics, Inc., and the Chief Medical Officer and Head of R&D at Neurotrauma Sciences. Anthony is also the Chair of the Medical and Scientific Advisory Board at Constant Therapeutics, where they are leading clinical programs for COVID-19, chronic stroke recovery, epidermolysis bullosa, and cardiomyopathy associated with Duchenne Muscular Dystrophy. Prior to this, they were the Chief Medical Officer at Cognition Therapeutics and the Interim Chief Medical Officer at Aeromics Inc., where they advised on first-in-human and proof of concept trials for an intravenously administered aquaporin-4 (AQP4) inhibitor. Anthony has also held positions with increasing accountability at Acorda Therapeutics, Inc. ranging from Senior Scientist to Senior Vice President of Research and Development. In 1999, they founded and served as the CEO of Remote Diagnostic Imaging.

Anthony Caggiano, MD, PhD earned their MD, PhD in Neuroscience and Medicine from The University of Chicago Pritzker School of Medicine between 1992 and 1999. Prior to this, they obtained a BA in Chemistry, Biology and Psychology from the University of Virginia between 1988 and 1992.